Clinical trials
Tolerance clinical trials
Below are recruiting tolerance clinical trials, each written for real people, not researchers. We’re tracking 950 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07035002RecruitingPhase 1
PD-1 knockout TILs for advanced colorectal cancer
This trial tests a new therapy where immune cells (TILs) from your tumor are modified to fight cancer more effectively. It's for people with advanced colorectal cancer who can't get standard treatments.
Shanghai, None SelectedAges 18–70 - NCT07035769RecruitingPhase 1
Debio 1453P safety study in healthy adults
This trial tests an experimental oral drug, Debio 1453P, for the first time in people. Healthy adults can take part to see if the drug is safe and how the body processes it.
EdegemAges 18–55 - NCT07035990RecruitingPhase 1
Testing combinations of three study drugs in healthy volunteers
This trial tests how safe and tolerable three different study drugs (SION-451, SION-2222, and SION-109) are when taken together in healthy adults. The goal is to find a good dose combination for future studies in people with cystic fibrosis.
Brisbane, QueenslandAges 18–55 - NCT07038382RecruitingPhase 2
Study of HLX79 with Rituximab for Active Kidney Disease
This trial tests a new drug called HLX79 (a human sialidase fusion protein) combined with rituximab, compared to a placebo, for people with active membranous nephropathy (a kidney disease). It aims to see if this combination can reduce protein in the urine and improve kidney function.
BeijingAges 18–75 - NCT07040930RecruitingPhase 1
Testing the safety of GenSci120 in healthy adults
This study tests a new drug called GenSci120, given as multiple injections under the skin, to see if it is safe in healthy adults. It will also measure how the drug moves through the body and how it affects certain immune markers.
Shanghai, Shanghai MunicipalityAges 18–55 - NCT07046559RecruitingPhase 1
Testing a new drug's safety in healthy volunteers
This trial is testing an experimental drug called LY4066708 in healthy people to see how safe it is and how the body processes it. It may help researchers understand if the drug can be used in future studies for conditions like Alzheimer's disease.
Holbeck, LeedsAges 18–65 - NCT07051629RecruitingPhase 1
Testing a new epilepsy medicine for safety in healthy people and patients
This study tests a new medicine called SIF001 for safety. It first gives the medicine to healthy volunteers, and then to people with epilepsy who have seizures even while on their current medicines. The goal is to find a safe dose.
Tucson, ArizonaAges 18–70 - NCT07058779RecruitingPhase 1
Safety study of SSS55 in healthy volunteers
This trial is testing a new medicine called SSS55 in healthy adults to see if it is safe and how the body processes it. Participants will receive meningococcal and pneumococcal vaccines before the study.
Shanghai, Shanghai MunicipalityAges 18–45 - NCT07061288RecruitingPhase 1
Testing a new injectable medicine for schizophrenia
This trial tests a new injectable form of KarXT for schizophrenia. It aims to see if the medicine is safe, tolerable, and how it works in the body.
Los Alamitos, CaliforniaAges 18–55 - NCT07063251RecruitingEarly Phase 1
Gene therapy safety study for Stargardt disease in teens
This study tests a new gene therapy called HG005 for Stargardt disease in young people aged 6 to 17. It aims to see if the treatment is safe and tolerable, and how well it works.
ShanghaiAges 6–17 - NCT07070999RecruitingPhase 1/Phase 2
Gene therapy GB221 for infants with SMA type 1
This trial tests a new gene therapy called GB221 for infants with SMA type 1, a rare muscle-weakening disease. It aims to see if this treatment can improve muscle strength and development, and it is for babies who have not had prior gene therapy.
Porto Alegre, Rio Grande do SulAges 2 weeks–1 year - NCT07072611RecruitingEarly Phase 1
Safety study of SOF-SKN cream in healthy volunteers
This study tests a cream called SOF-SKN on healthy people to see if it's safe and how the body handles it. It is a first-in-human trial, so if you join, you'll help researchers learn about the cream before testing it in patients.
Melbourne, VictoriaAges 18–64 - NCT07073547RecruitingPhase 1
Study of AZD0120 for multiple myeloma patients
This trial tests a new drug, AZD0120, in people with multiple myeloma. It aims to find the right dose and see how safe and effective it is. The study includes both newly diagnosed and early relapsed patients.
Phoenix, ArizonaAges 18 years+ - NCT07073638RecruitingPhase 2
Testing a new TB drug called RESP30TB in people with newly diagnosed TB
This trial tests a new drug, RESP30TB, to see if it is safe, tolerable, and can quickly kill TB bacteria in people with newly diagnosed, rifampicin-susceptible pulmonary TB. You may be eligible if you can produce sputum and meet other health criteria.
Cape Town, BellvilleAges 18–65 - NCT07080775RecruitingPhase 1
Testing a new injection for Parkinson's disease
This trial tests an injection called XS411CN for people with Parkinson's disease whose current medications are not working as well as before. The goal is to see if it is safe and tolerable.
Beijing, Beijing MunicipalityAges 50–75 - NCT07085507RecruitingPhase 1/Phase 2
Testing a new drug for multiple sclerosis in healthy people and MS patients
This trial tests an experimental oral drug called VT7208 in both healthy volunteers and people with multiple sclerosis (MS). The goal is to see if it is safe and how the body processes it, which could lead to a new treatment option for MS.
Adelaide, South AustraliaAges 18–65 - NCT07092423Recruiting
Special liquid tube feed for brain injury patients
This study tests a special liquid formula (semi-elemental nutrition) given through a feeding tube to people with severe traumatic brain injury. It aims to see if this formula is easier on the stomach and causes fewer digestive problems than standard tube feeds.
Xi'an, ShaanxiAges 18–75 - NCT07095127RecruitingPhase 2
Testing NVG-2089 for immune thrombocytopenia
This trial tests an investigational drug called NVG-2089 for adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. The goal is to see if it safely raises platelet counts and improves bleeding symptoms.
Greenville, North CarolinaAges 18–80 - NCT07098663RecruitingPhase 2
Study of MKP10241 for weight loss and diabetes control
This study tests an investigational drug called MKP10241 in healthy people, people with obesity, and people with type 2 diabetes. It aims to see how the drug affects blood sugar, weight, and overall safety. It may be an option if you have obesity or type 2 diabetes managed by diet and/or metformin.
Bayswater, VictoriaAges 18–60 - NCT07099118RecruitingPhase 1
Safety and tolerability of HEC169584 in healthy people
This early-stage study checks if a new medicine called HEC169584 is safe for people and how it moves through the body. It looks for healthy volunteers to take part.
Beijing, Beijing MunicipalityAges 18–45 - NCT07102251RecruitingPhase 1
Safety study of HEC-007 injection in healthy and overweight people
This trial tests a new injection, HEC-007, to see if it is safe in healthy adults and in people who are overweight or obese. It may help with weight management and related health issues.
Hefei, AnhuiAges 18–65 - NCT07102342RecruitingPhase 1/Phase 2
Cell therapy for Parkinson's disease
This trial tests a new cell treatment for Parkinson's disease. It involves injecting special cells into the brain to see if they can safely replace damaged cells and improve symptoms. It might help people who have had Parkinson's for several years and still respond well to medication.
New York, New YorkAges 30–75 - NCT07102394RecruitingPhase 1
Testing talimogene laherparepvec for skin bumps in adults with NF1
This trial tests a drug called IMLYGIC (talimogene laherparepvec) to see if it is safe and tolerable for treating skin bumps (cutaneous neurofibromas) in adults with NF1. The drug is injected directly into the bumps, and the study will check if it can shrink them or improve symptoms.
Baltimore, MarylandAges 18 years+ - NCT07104565RecruitingPhase 2
Tafasitamab for autoimmune blood cell disorders
This study tests a new drug, tafasitamab, for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that has not been controlled well by other treatments. The goal is to see if it is safe and can help manage these blood cell disorders.
Glendale, ArizonaAges 18 years+
Hear when a new Tolerance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tolerance?
- Yes. Clin2 currently lists 950 recruiting tolerance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tolerance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tolerance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.